The field of cancer research and development has expanded tremendously courtesy of modern biotechnology companies. As a biotech company, Seattle Genetics has always been on the verge of contributing to cancer research. The biotechnology giant attributes most of its success to its CEO, Clay Siegall. During Siegall’s leadership tenure, Seattle Genetics’ stock value tripled in five years.
Siegall’s Career Background
Besides the stock price success, Clay Siegall has facilitated several advances in Seattle Genetics. He is regarded as one of the founders of the company. He began working for the company as CEO back in 2002. Siegall qualified for the CEO role because of his expertise in biomedical research. He also attended George Washington University for his doctoral degree in genetics.
Siegall’s biomedical research expertise has benefited companies such as Bristol-Meyers Squibb Pharmaceutical Research Institute. The institution had hired him as the senior research investigator and later promoted him to the principal scientist. Siegall has also worked with the National Cancer Institute as biotechnology fellow and a staff fellow.
Siegall’s Leadership Strategies
According to Clay Siegall, professional achievements can only be attained through commitment and diligence. Throughout his career, Siegall has always focused on important research. He has also been diligent in the implementation of state-of-the-art research developments. His desire to help cancer patients has proved to be beneficial to his professional career.
Siegall was one of the pioneers of Seattle Genetics’ antibody-drug conjugate (ADC) technology. One of the company’s products developed using the technology is ADCETRIS. This innovative medication was approved for use in the cancer therapy field. Seattle Genetics also availed the drug in over 60 countries across the globe.
Awards and Accolades
In 2013, the University of Maryland named Clay Siegall as a recipient of the Alumnus of the Year for Computer, Math, and Natural Sciences. Siegall was also awarded the Pacific Northwest Ernst & Young Entrepreneur of the Year Award in 2012. These awards were meant to recognize Siegall’s relevance in the cancer research community. They also acknowledge his efforts in facilitating a fundraiser for Seattle Genetics that amassed over 1.2 billion.